The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, as well as for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trial for the treatment of acute bacterial skin and skin structure infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company’s products under development also comprise MDCO-157, a pre-registration stage product for platelet inhibition in patients suffering from acute coronary syndrome (ACS); MDCO-216, a novel biologic product that is in Phase I trial to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program, which is in Phase I trial for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Key Statistics